Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Unicycive Therapeutics (NASDAQ:UNCY) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.09, Zacks reports.

Unicycive Therapeutics Price Performance

Shares of UNCY opened at $0.55 on Friday. The business’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.61. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.08. The stock has a market capitalization of $66.42 million, a PE ratio of -0.57 and a beta of 2.14.

Analyst Upgrades and Downgrades

A number of research analysts have commented on UNCY shares. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They set a “buy” rating and a $6.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of Unicycive Therapeutics in a research report on Friday, April 11th.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.